The PI3K inhibitor BKM120 has potent antitumor activity in melanoma brain metastases in vitro and in vivo

被引：0
|
作者：
Niessner, H. [1 ]
Forschner, A. [1 ]
Schmitz, J. [2 ]
Schmid, A. [2 ]
Calaminus, C. [2 ]
Sinnberg, T. [1 ]
Tabatabai, G. [3 ]
Quintanilla-Fend, L. [4 ]
Pichler, B. J. [2 ]
Garbe, C. [1 ]
Meier, F. [1 ]
机构：
[1] Univ Tubingen, Dept Dermatol, D-72076 Tubingen, Germany
[2] Univ Tubingen, Dept Preclin Imaging & Radiopharm, D-72076 Tubingen, Germany
[3] Univ Zurich Hosp, Dept Neurol, CH-8091 Zurich, Switzerland
[4] Univ Tubingen, Dept Pathol, D-72076 Tubingen, Germany
来源：
EXPERIMENTAL DERMATOLOGY | 2014年 / 23卷 / 03期
关键词：
D O I：
暂无
中图分类号：
R75 [皮肤病学与性病学];
学科分类号：
100206 ;
摘要：
引用
收藏
页码：E43 / E43
页数：1
相关论文
共 50 条
  • [1] The PI3K inhibitor BKM120 has potent antitumor activity in melanoma brain metastases in vitro and in vivo
    Meier, Friedegund Elke
    Niessner, Heike
    Schmitz, Jennifer
    Schmid, Andreas
    Calaminus, Carsten
    Pichler, Bernd
    Forschner, Andrea
    Flaherty, Keith
    Honegger, Juergen Bernd
    Dummer, Reinhard
    Tabatabai, Ghazaleh
    Weide, Benjamin
    Eigentler, Thomas K.
    Schadendorf, Dirk
    Quintanilla-Fend, Leticia
    Garbe, Claus
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [2] The PI3K Inhibitor BKM120 has Potent Antitumor Activity in Melanoma Brain Metastases In Vitro and In Vivo
    Niessner, H.
    Schmitz, J.
    Schmid, A.
    Calaminus, C.
    Pichler, B. J.
    Forschner, A.
    Flaherty, K.
    Honegger, J. B.
    Dummer, R.
    Tabatabai, G.
    Quintanilla-Fend, L.
    Garbe, C.
    Meier, F.
    JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT, 2013, 11 : 5 - 5
  • [3] The PI3K inhibitor BKM120 inhibits growth of pancreatic ductal adenocarcinoma in vitro and in vivo
    Tignanelli, Christopher James
    Herrera, Silvia Gabriela
    Torphy, Robert
    Yeh, Jen Jen
    JOURNAL OF THE AMERICAN COLLEGE OF SURGEONS, 2013, 217 (03) : S137 - S138
  • [4] PI3K Pathway Inhibition Achieves Potent Antitumor Activity in Melanoma Brain Metastases In Vitro and In Vivo
    Niessner, Heike
    Schmitz, Jennifer
    Tabatabai, Ghazaleh
    Schmid, Andreas M.
    Calaminus, Carsten
    Sinnberg, Tobias
    Weide, Benjamin
    Eigentler, Thomas K.
    Garbe, Claus
    Schittek, Birgit
    Quintanilla-Fend, Leticia
    Bender, Benjamin
    Mai, Marion
    Praetorius, Christian
    Beissert, Stefan
    Schackert, Gabriele
    Muders, Michael H.
    Meinhardt, Matthias
    Baretton, Gustavo B.
    Dummer, Reinhard
    Flaherty, Keith
    Pichler, Bernd J.
    Kulms, Dagmar
    Westphal, Dana
    Meier, Friedegund
    CLINICAL CANCER RESEARCH, 2016, 22 (23) : 5818 - 5828
  • [5] Hydroxychloroquine synergizes with the PI3K inhibitor BKM120 to exhibit antitumor efficacy independent of autophagy
    Peng, Xin
    Zhang, Shaolu
    Jiao, Wenhui
    Zhong, Zhenxing
    Yang, Yuqi
    Claret, Francois X.
    Elkabets, Moshe
    Wang, Feng
    Wang, Ran
    Zhong, Yuxu
    Chen, Zhe-Sheng
    Kong, Dexin
    JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH, 2021, 40 (01)
  • [6] Correction to: Hydroxychloroquine synergizes with the PI3K inhibitor BKM120 to exhibit antitumor efficacy independent of autophagy
    Xin Peng
    Shaolu Zhang
    Wenhui Jiao
    Zhenxing Zhong
    Yuqi Yang
    Francois X. Claret
    Moshe Elkabets
    Feng Wang
    Ran Wang
    Yuxu Zhong
    Zhe-Sheng Chen
    Dexin Kong
    Journal of Experimental & Clinical Cancer Research, 40
  • [7] PRE-CLINICAL ACTIVITY OF THE PI3K INHIBITOR BKM120 ON ACUTE MYELOID LEUKEMIA
    Allegretti, M.
    Ricciardi, M. R.
    Licchetta, R.
    Mirabilii, S.
    Amadori, S.
    Foa, R.
    Tafuri, A.
    HAEMATOLOGICA, 2014, 99 : 291 - 291
  • [8] Effective use of PI3K inhibitor BKM120 to treat human osteosarcoma
    Lu, Yao
    Wang, Qian
    Fan, Shan
    Hu, Bin
    Sun, Liang
    Xue, Hanzhong
    Zhou, Chengpei
    Zhou, Yong
    Zhang, Kun
    Li, Zhong
    Ma, Teng
    INTERNATIONAL JOURNAL OF CLINICAL AND EXPERIMENTAL MEDICINE, 2017, 10 (04): : 6378 - 6386
  • [9] Inhibition of the PI3K pathway with buparlisib (BKM120) is a suitable strategy to overcome therapy resistance in melanoma-derived brain metastasis in vitro and in vivo
    Niessner, H.
    Schmitz, J.
    Schmid, A.
    Sinnberg, T.
    Tabatabai, G.
    Weide, B.
    Garbe, C.
    Quintanilla-Fend, L.
    Beissert, S.
    Kulms, D.
    Pichler, B.
    Meier, F.
    EXPERIMENTAL DERMATOLOGY, 2015, 24 (03) : E32 - E32
  • [10] BKM120 is cytotoxic in neuroblastoma targeting the PI3K pathway
    Pomaville, Monica M.
    Zhao, Ping
    Decou, Sarah
    Nagulapally, Abhinav B.
    Bond, Jeffrey
    Sholler, Giselle L. Saulnier
    CANCER RESEARCH, 2016, 76
12345